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Abstract  
 
Objective: The objective of this selective EBM review is to determine whether or not 
pomalidomide plus low dose Dexamethasone is an effective and safe treatment for patients with 
relapsed or refractory multiple myeloma (RRMM). 
 
Study Design: Review of three open-label clinical trials with one published in 2012 and two 
published in 2013. 
 
Data sources: Two randomized, open-label, phase 2 clinical trials and one open-label phase 3 
clinical trial evaluating efficacy of pomalidomide plus low dose dexamethasone and its safety 
were found using the PubMed database. 
 
Outcomes measures: Efficacy of pomalidomide plus low-dose dexamethasone was measured by 
overall response rates (ORR) to the treatment according to the International Myeloma Working 
Group Criteria/European Group for Blood and Marrow Transplantation criteria.9,10 Safety profile 
of the treatment regiment was assessed through measuring ANC looking for neutropenia.  
 
Results: The studies by Richardson, et al. and Miguel et al. found pomalidomide plus low-dose 
dexamethasone led to an increased number of patients responding to treatment compared to 
controls as well as decreased cases of neutropenia.3,4 The study by Leleu et. al. found the 28 day 
cycle of pomalidomide plus weekly 40 mg of dexamethasone with pomalidomide on days 1-21 
had a more favorable safety profile for patients compared to pomalidomide on days 1-28.2 
 
Conclusions: Based on analysis of these 3 randomized controlled trials, pomalidomide plus low 
dose dexamethasone is a safe and effective treatment option for RRMM. The open-label design 
of these studies warrants further follow-up with patients who are continuing with these studies to 
further verify the results established in these reviews.  
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Introduction: 
 
Multiple myeloma (MM) is a blood cancer causing uncontrolled proliferation of plasma 
cells leading to bone destruction, kidney damage and anemia.1 MM is the most common primary 
bone cancer and the second most common hematologic cancer accounting for 1% of all cancers. 
Unfortunately, MM treatments are limited and all patients with this disease will relapse or 
become refractory to treatment in a relatively short period of time.2,3,4  The 5-year survival rate 
for myeloma patients is now up to 45%, however more improvement is needed.5 New 
medications to treat this disease will offer hope to patients with multiple myeloma. This 
represents why understanding the efficacy of novel agents is crucial to practicing physician 
assistants who will come into contact with these patients.  
Treating cancer is very expensive and multiple myeloma is not any different. It is 
difficult to estimate the exact amount treatment costs due to the amount of individualized 
therapies and varying stages. However, daily costs for treatments with drugs such as 
Lenalidomide are around $428 per day. Treatment costs for newer agents, such as 
Pomalidomide, can cost over $121,000 per year when patients become refractory to treatments or 
relapse.5   
Patients with multiple myeloma will require many healthcare visits and PA’s will play a 
vital role in their care. These patients will need continuous monitoring, not only by their 
oncologist, but by their primary care provider (PCP) as well, due to increased morbidity due to 
weakened immune systems from chemotherapy, steroids, etc. The amount of healthcare visits a 
myeloma patient will require is dependent on the individual and their stage of the cancer. Each 
patient will spend weeks to months in the hospital for treatments such as stem cell transplants 
and weakened immune defenses due to neutropenia. These patients are also more prone to 
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infection and viral illness requiring multiple visits to their PCP. Periods of remission still require 
frequent visits for laboratory testing to monitor serum monoclonal protein antibodies.1  
Multiple myeloma has been extensively researched and more information about the 
disease becomes available every year. The pathogenesis of multiple myeloma offers key insight 
into how the disease functions and why it is so difficult to treat.7 Etiology of disease is another 
essential factor in determining the most effective treatments. Unfortunately, the causes of 
multiple myeloma are unknown. It is believed to be a summation of environmental and genetic 
factors leading to multiple gene mutations causing heterogeneous tumors of proliferating plasma 
cells.8 These factors make treatment difficult and even more difficult for refractory/relapse 
patients who have more limited options.  
Current treatment options are dependent upon age of onset and stage and health of the 
patient at initial presentation. The gold standard in providing years of remission for most patients 
is a stem cell transplant, however the procedure has a high morbidity and mortality rate.8 
Chemotherapy remains the most common treatment for myeloma and represents the treatment of 
choice for most patients. Agents such as bortezomib and thalidomide derivatives with or without 
dexamethasone are the current standards of therapy. However, when patients relapse or become 
refractory to these treatments they are no longer effective.8 For this reason, novel treatments for 
myeloma are needed. The increase in 5-year survival rates, from 26% to 45%, in the last 30 years 
prove that new treatments are effective.5  
Pomalidomide is a newer derivative of thalidomide that may provide myeloma patients 
another option when they have refractory or relapsed disease. Various clinical trials with 
pomalidomide have proven the agent effective in reducing plasma cell counts in this particular 
population. In addition, when combined with dexamethasone, pomalidomide increases the 
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amount of people who will respond to the treatment.2,3,4 Although myeloma cannot be cured, 
ongoing advances in treatments are leading to longer remission periods and more treatment 
options that extend the life of those affected by this challenging disease.  
This paper evaluates three randomized controlled trials comparing the efficacy of the 
novel agent pomalidomide alone or in combination with dexamethasone in patients with relapsed 
or refractory MM and its efficacy in reducing plasma cell proliferation rate.  
 
Objective: 
 
The objective of this selective EBM review is to determine whether or not pomalidomide 
plus low dose Dexamethasone is an effective and safe treatment for patients with relapsed or 
refractory multiple myeloma regardless of age, sex or gender.  
 
Methods: 
 
The studies chosen for this review involved using pomalidomide plus low dose 
dexamethasone in patients with relapse or refractory multiple myeloma (RRMM) with failed 
attempts at standard therapies. Table 1 provides more information on the demographics of these 
studies. All patients were treated with a pomalidomide PO (4mg) plus dexamethasone PO 
(40mg) combination over a 28 day cycle. Comparison groups included longer continuous time on 
pomalidomide, receiving pomalidomide alone and also receiving only dexamethasone. The 
outcomes measured in all of these studies were overall response rates (ORR), in accordance the 
to the international myeloma working group criteria,9,10 as well as safety profile of the drug 
combination by measuring absolute neutrophil count. The types of studies included were two 
randomized, open-label, phase 2 clinical trials by Richardson, et al. and Leleu et al. as well as 
one open-label phase 3 clinical trial evaluating pomalidomide plus low dose dexamethasone 
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written by Miguel et al. Overall response rates were calculated using intention to treat 
populations as well the efficacy evaluable population.   
The key words used to find these articles included myeloma, relapsed/refractory and 
pomalidomide. Each article was published in English in peer-reviewed journals and researched 
by the author. All articles were found using the PubMed database. Cochrane Systematic Reviews 
was also used to verify no past reviews of this topic. The articles were selected based on 
relevance and inclusion of patient oriented outcomes (POEM) as an evaluation criterion. 
Inclusion criteria for systematic reviews included randomized, controlled, clinical trials and 
patients previous treatments attempted. Exclusion criteria included any phase 1 studies or 
publication date prior to 2012 as well as non-patient oriented outcomes. Reported statistics that 
were used include p-values and 95% confidence intervals. Numbers needed to treat (NNT) and 
numbers needed to harm (NNH) were calculated by the author.  
Table 1: Demographics of each study  
Study Type #Pt Age 
(yrs) 
with 
range 
Inclusion 
Criteria 
Exclusion 
Criteria 
W/D Intervention 
and Safety 
Profile 
Richardson, 
et. al, 2013 
Multicenter, 
open-label, 
randomized 
Phase 2 
study 
113 64 (34-
88) 
≥ 18 yo, 
RRMM, 
measurable M-
paraprotein 
level, ≥2 
previous failed 
therapies 
ANC < 1000/µL, 
platelet count < 
75,000/µL, serum 
creatinine ≥ 3.0 
mg/dL, serum 
liver transaminase 
levels > 3.0 or 
serum bilirubin > 
2.0 mg/dL 
108 -Pomalidomide 
4 mg/day PO on 
days 1-21 of 
each 28-day 
cycle with 
dexamethasone 
40 mg/week PO 
- Neutropenia  
Leleu, et. 
al., 2012 
Multicenter, 
open-label, 
randomized 
Phase 2 
study 
43 60 (45-
81) 
RRMM after ≥ 
prior regime of 
treatment and 
failure,    
measurable 
disease, platelet 
count ≥ 75 X 
109/L, 
Not meeting 
inclusion criteria 
35 - 28 day cycle 
of 
Pomalidomide 
PO 4 mg/day on 
days 1-21 + 
Dexamethasone 
40mg PO QWK 
- Neutropenia 
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neutrophils ≥ 1 
X 109/L and 
creatinine 
clearance ≥ 50 
mL/min. 
San Miguel, 
et. al., 2013 
Randomized, 
open-label, 
phase 3 trial 
302 64 (35-
84) 
RRMM and 
have failed two 
previous 
treatments with 
Bortezomib and 
lenalidomide. 
Resistance to 
Bortezomib, 
Pomalidomide 
treatment 
previously or 
hypersensitivity to 
dex. or 
Pomalidomide.  
242 - 28 day cycle 
of 
pomalidomide 
PO (4 mg/day 
on days 1 – 21) 
+ low dose 
dexamethasone 
PO (40 mg/day 
on days 1, 8, 15 
and 22)  
- Neutropenia  
 
Outcomes: 
 
Overall response rates to the treatment combination in these studies were determined 
according to the International Myeloma Working Group criteria.9,10 Patients who had greater 
than or equal to partial responses were considered in the calculation of overall response rates in 
each article. Adverse reactions were addressed via patients presenting with neutropenia 
objectively measured by absolute neutrophil count (ANC).  Decreased ANC can predispose 
patients to an increased risk of infections including, but not limited to, pneumonia and sepsis.  
Results: 
 
The analysis of these three open-label clinical trials allowed for an evidence based 
medicine review of the effectiveness of pomalidomide plus low dose dexamethasone in the 
treatment of relapsed and refractory multiple myeloma. The search criteria used in this review 
enabled evaluation of the most recent studies to provide an answer to the question addressed in 
this study. This review included two randomized, open-label, phase 2 clinical trials and one 
open-label phase 3 clinical trial all published in 2013 and 2014. Richardson, et al. and Leleue, et 
al. both compared pomalidomide 4 mg per day PO on days 1-21 of each 28-day cycle with 
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dexamethasone 40 mg per week PO versus pomalidomide 4 mg per day PO on days 1-21 of each 
28-day cycle without dexamethasone or 28 days continuous pomalidomide, respectively, in 
multicenter, open-label, randomized phase 2 studies.2,4 Miguel, et al. compared a 28 day cycle of 
pomalidomide PO (4 mg per day on days 1 – 21) plus low dose dexamethasone PO (40 mg per 
day on days 1, 8, 15 and 22) verse 28 day cycles of high dose dexamethasone PO 40 mg per day 
on days 1-4, 9-12 and 17-20 in a randomized, open-label, phase 3 clinical trial.3 
Inclusion criteria included patients who have tried and failed other myeloma treatments, 
older than 18 years old and measureable serum M-protein levels. Each study had it’s own 
exclusion criteria. Richardson, et al. had the largest amount of exclusion criteria enabling this 
article to highlight the safety profile of pomalidomide plus low dose dexamethasone and not due 
to co-morbidity of the disease. They specifically excluded patients coming into the study with an 
already reduced ANC level. Miguel, et al. excluded patients who have previously tried 
pomalidomide as well as those trying other novel agents such as brotezomib.  
Richardson, et al. had 221 patients with an average time on treatment of 14.2 months. 
They saw an ORR 33% of patients on pomalidomide plus low dose dexamethasone compared to 
18% in the pomalidomide alone group (95% CI = 1.21 – 2.49, p = 0.013).  Special patient 
populations were also analyzed. Patients 65 years old or older showed a greater overall response 
rate of 35% when compared to patients younger than 65 years old at 31%. No p-values or 
confidence intervals reported. Five patients were divided into an extramedullary disease category 
with only 1 obtaining an ORR on pomalidomide plus low dose dexamethasone. Other 
populations include Lenalidomide-refractory disease, Lenalidomide and Bortezomib- refractory 
disease, lenalidomide as last prior therapy and prior carfilzomib. Results for these populations 
can be seen in table 2.4  
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Table 2: Overall Response Rates according to patient population (Richardson et al.)  
Population Subgroup  Pom + LoDEX Pom Alone P-value  
Lenalidomide refractory  30% 21% 0.224 
Lenalidomide and Bortezomib refractory
  
31% 21% 0.243 
Lenalidomide as last therapy 25% 15% Not Reported  
Prior carfilzomib 37% 10% 0.030 
 
The study by Leleu, et al. included 84 patients with an average treatment time of 22.8 
months. An ORR of 35% was seen in the group receiving pomalidomide for 21 to 28 days verse 
a 34% overall response rate in the group receiving pomalidomide for 28 days (p = 0.817). 
Several subgroups were also analyzed. Patients 65 years old or older had an overall response rate 
of 27% across both arms of this study. Patients with poor cytogenetic abnormalities and those 
refractory to previous therapies were also evaluated as seen in table 3. These patients were not 
divided into treatment arms but observed as a whole. No p-values or confidence intervals were 
reported for these special populations.2 
Table 3:  Overall response rates in patients with cytogenetic abnormality and various 
resistance to therapy (leleu et al.)  
Population Subgroup ORR 
Lenalidomide refractory 36% 
Lenalidomide as last treatment 23% 
Bortezomib refractory 29% 
Refractory to bortezomib and lenalidomide 31% 
More than 6 therapies 21% 
Del 17p and/or t(4;14) 27% 
The study by Miguel, et al. included 455 patients with an average time on treatment of 10 
months. There was a significant difference (p<0.0001) between the population receiving 
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pomalidomide plus low dose dexamethasone (ORR of 31%) compared to the high-dose 
dexamethasone alone group (ORR of 10%). Various subgroups were also analyzed in this study 
including those resistant to lenalidomide, brotezomib and the combination. Others included 
lenalidomide or brotezomib as last treatment. ORR for these subgroups can be found in table 4. 
No p-values or confidence intervals were provided for these subgroups.3 
Table 4:  Overall response rates according to patient population (Miguel et al.)  
Subgroup Pom + DEX DEX alone 
Lenalidomide refractory 30% 9% 
Bortezomib intolerance 31% 13% 
Lenalidomide + Bortezomib refractory 28% 12% 
Lenalidomide as last treatment 33% 6% 
Bortezomib as last therapy  34% 12% 
 
Table 5 summarizes the ORR, duration of treatment and numbers needed to treat of 
pomalidomide plus low dose dexamethasone in the three studies used in this review. Richardson, 
et al. needed to treat 7 people in order to achieve one more with ORR to therapy compared to 
their control.4 Leleu, et al. found they needed to treat 100 patients in order for one more 
response.2 Miguel, et al. found they needed to treat 5 patients in order to achieve one more with a 
response.3  
Table 5: Summary of ORR vs. comparison with treatment duration, NNT and P-value 
Study Treatment ORR Average Duration 
of  
Treatment 
NNT Sig.   
(p-
value) 
Richardson, et al. Pom (day 1-21)+ LoDEX 
(40 mg weekly) 
33% vs. 18% 14.2 months 7 0.013 
Leleu, et al. Pom (day 1-21) + LoDEX 
(40 mg weekly) 
35% vs. 34%  22.8 months 100 0.817 
Miguel, et al. Pom (day 1-21) + LoDEX 
(40 mg weekly) 
31% vs. 10% 10 months 5 <0.0001 
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The most common adverse reaction in all studies was neutropenia.2,3,4 Richardson, et al. 
saw 41% of patients develop neutropenia while on pomalidomide plus dexamethasone versus 
48% of patient in pomalidomide alone group. There were not any p-values or confidence 
intervals provided. For every fourteen patients treated, one fewer case of neutropenia was noted 
with experiment verse control. There were 3% of patients on pomalidomide plus dexamethasone 
that developed severe neutropenia requiring termination of treatment.4 Leleu, et al. found 
neutropenia present in 65% of patients on the 21 day arm of pomalidomide plus dexamethasone 
compared to 58.5% of patients on the 28 day arm.2 For every fifteen patients treated, one more 
case of neutropenia developed. No patients had to stop due to toxicity of the drug. Miguel, et al. 
found neutropenia in 51% of patients on pomalidomide plus dexamethasone compared to 21% of 
patients on high-dose dexamethasone.3 For every four patients treated, one more patient 
developed neutropenia compared to control. 2% of patients had to discontinue therapy due to 
fever with neutropenia. Table 6 summarizes these results as well as number needed to harm.  
Table 6: Neutropenia in Pom + LoDEX groups  
Study Treatments NNH Pts withdrawal due to ADR 
Richardson, et al. Pom + LoDex vs. Pom alone  -14 3% vs. 5% 
Leleu, et al. Pom + LoDex (21 day vs. 28 day) 15 0% vs. 5% 
Miguel, et al. Pom + LoDex vs. High dose DEX 4 2% vs. 0% 
 
Discussion: 
 
This systematic review investigated the effectiveness and safety of pomalidomide plus 
low dose dexamethasone in relapsed/refractory multiple myeloma. All three studies have 
demonstrated that this drug combination is an effective and safe in the management of RRMM. 
The synergistic effects of this drug combination have anti-proliferative actions on plasma cells.4 
The use of immunomodulatory drugs, such as pomalidomide, warrants expectations of adverse 
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reactions.  These drugs inhibit angiogenesis and decrease cytokine production leading to cell 
arrest and apoptosis within any tissue of the body.11 However, the evidence proves sufficient to 
state pomalidomide is safe and well tolerated.2,3,4 Patients who present with neutropenia should 
be monitored constantly and treated aggressively with any signs of infection.12 As demonstrated 
in this review, few patients needed to discontinue treatment due to sever neutropenia with 3% of 
patients being the highest.4 It must be noted that patients should stop pomalidomide with severe 
neutropenic fever and have dose reduced when the fever subsides.8  
Most patients will be able to take pomalidomide but few contraindications exist. Some 
contraindications exist including pregnancy, an allergy to the medicine or those who already 
have neutropenia. The exclusion criteria in these studies were limited and highlight the 
importance of finding new treatments. More patients were able to qualify for this study and 
receive the treatments their lives were dependent upon. The exclusion criteria are also limited to 
make sure those selected for the study were representative of patients with RRMM who have 
significant history of failed treatments.  
It is important to understand the maximum tolerated dose of pomalidomide plus 
dexamethasone to maintain efficacy while decreasing adverse reactions. Phase 1 studies of these 
articles have demonstrated the maximum tolerated dose to be 4 mg per day.2 These studies have 
shown 4 mg/day of pomalidomide on day 1-21 with weekly 40 mg of dexamethasone to be the 
most beneficial therapy when compared to 28 straight days of pomalidomide.2  
Although pomalidomide is expensive, its availability is not an issue in the United States. 
Insurances would like proper authorization and demonstration of medical necessity prior to 
initiation. However, the patient population who will need these drugs will continue to grow and 
the cost of the drug will hopefully become lower.  
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A couple important challenges in this study are the number of patients who would need 
moved from a comparison group to pomalidomide plus low dose dexamethasone group as well 
as the number of patients who had to withdraw due to disease progression. This creates overall 
response rates that may not be as accurate, however patients who required a change in groups 
were accounted by using efficacy evaluable populations and intention to treat analysis. The 
amount that withdrew at time of analysis will be more critical to open-label design of these 
studies. As time continues the population in the study will become too small for an effective 
analysis. RRMM is a rapid and progressive disease demonstrating the difficulty in performing 
long-term studies with these novel agents. 
Conclusion: 
 
This review has demonstrated pomalidomide plus low dose dexamethasone is an 
effective and safe treatment for patient with relapsed/refractory multiple myeloma. These open-
label studies remain ongoing and more publications are expected in the future. 
Pomalidomide alone was not as effective as the combination with dexamethasone. This 
warrants further investigation into the mechanism of action of these drugs to enhance efficacy. 
Continuing studies on pomalidomide can observe various combinations of pomalidomide and 
other novel agents searching for similar synergistic effects as when combined with 
dexamethasone. In addition, studies that analyze patients with specific previous treatments will 
help determine the best treatments for these specific patients when they relapse. These studies 
can further be divided into specific age groups to further customize treatments.  
Research provides RRMM patients with new hope and extended life. As time continues 
we can only hope that more novel agents will come out to treat this disease and ultimately lead to 
a cure. 
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